TrialScientific reports2019

Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial.

Ping Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.